Worsening of tardive dyskinesia due to clozapine therapy

Raguraman, Janakiraman; Vijaysagar, J

doi:10.4103/0022-3859.33874

Cited by 9 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In such cases switching to clozapine may reveal suppressed TD (Bruscas et al, 2007;Duggal and Mendhekar, 2007;Ertugrul and Demir, 2005;Li et al, 2009;Raguraman and Vijaysagar, 2007). In the few case reports suggesting that clozapine induces TD most of the patients had a history of long-term use of FGAs.…”

Section: B Switching To Clozapinementioning

confidence: 99%

Tardive Dyskinesia: Clinical Presentation and Treatment

Harten

Tenback

2011

International Review of Neurobiology

View full text Add to dashboard Cite

Section: B Switching To Clozapinementioning

confidence: 99%

Tardive Dyskinesia: Clinical Presentation and Treatment

Harten

Tenback

2011

International Review of Neurobiology

View full text Add to dashboard Cite

“…Other treating clinicians that took a similar strategy did not recognize the same effect in their patient (Gafoor and Brophy, 2003; Mendhekar and Duggal, 2006; Miller, 2003). Three patients responded positively to clozapine discontinuation, such that their TD symptom severity improved (Asmal, 2009; Gafoor and Brophy, 2003; Raguraman and Vijaysagar, 2007).…”

Section: Resultsmentioning

confidence: 99%

Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review

et al. 2019

View full text Add to dashboard Cite

Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent. However, reports do indicate clozapine carries a liability for tardive dyskinesia. Aims: This review sought to evaluate clozapine in relation to tardive dyskinesia in the context of available evidence. Methods: Medline, Embase, and PsycINFO databases were searched for studies published in English, using the keywords: clozapine AND tardive dyskinesia OR TD. References from major review articles were searched for additional relevant publications. Studies were included if they investigated: tardive dyskinesia in clozapine-treated patients diagnosed with schizophrenia spectrum disorders, and reported on two or more assessments of tardive dyskinesia severity measured by the Abnormal Involuntary Movement Scale; or clozapine’s tardive dyskinesia liability. Results: In total, 513 unique citations were identified and 29 reports met the inclusion criteria. Thirteen studies suggest clozapine reduces dyskinetic symptoms over time ( n=905 clozapine-treated participants); however, the minimum required dose and effect of withdrawal requires further investigation. The majority of reports which address clozapine’s liability for tardive dyskinesia are case studies (11 of 14 reports, 79%), and clozapine was only the first-line treatment in one of the remaining three studies reporting treatment-emergent dyskinetic symptoms with clozapine in 12% of patients. No significant between-drug differences were identified comparing clozapine’s risk to other atypical antipsychotics. Conclusions: Research to date supports switching to clozapine for the purpose of reducing tardive dyskinesia risk and/or treating existing tardive dyskinesia, but prospective randomized controlled trials are necessary if we are to substantiate existing recommendations.

show abstract

“…However, the symptoms again recurred following rechallenge with clozapine, following which he was shifted to olanzapine. Raghuraman and Vijaysagar[44] described a case of 28-year-old male, diagnosed with schizophrenia and developed TD of upper limb and orofacial dyskinesia while receiving risperidone 6 mg/day. Due to the movement disorder, he was shifted to clozapine and the dose was titrated to 300 mg/day.…”

Section: Case Reports Reporting Side Effectsmentioning

confidence: 99%

Indian research: Focus on clozapine

Grover

Dutt

2010

Indian J Psychiatry

View full text Add to dashboard Cite

Clozapine has been used in the treatment of schizophrenia for about two decades and extensive data have been accumulated with regard to its use in various parts of the world. However, in contrast to Western countries, there are few studies which have evaluated the usefulness of clozapine in Indian patients. This article attempts to review the available data on clozapine originating from India. This review reflects the fact that there are few studies from the Indian subcontinent and most of these are case reports. In view of the same, there is a need for further research to evaluate the effectiveness of clozapine in India.

show abstract

Worsening of tardive dyskinesia due to clozapine therapy

Cited by 9 publications

References 2 publications

Tardive Dyskinesia: Clinical Presentation and Treatment

Tardive Dyskinesia: Clinical Presentation and Treatment

Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review

Indian research: Focus on clozapine

Contact Info

Product

Resources

About